Evidence of robust memory T‐cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)

Harrington, Patrick; Harrison, Claire; Dillon, Richard; Radia, Deepti; Rezvani, Katayoun; Raj, Kavita; Woodley, Claire; Garcia, Natalia Curto; O’Sullivan, Jennifer; Saunders, Jamie; Kordasti, Shahram; Ali, Sahra; Lavallade, Hugues de; McLornan, Donal

doi:10.1111/bjh.17402

Cited by 13 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a mixed cohort of SOT recipients, Favà et al demonstrated the development of robust serological and functional responses comparable to nontransplant patients during early convalescence 7 . Studies performed in other types of immunocompromised hosts have reached similar conclusions 19 . Overall, these findings emphasize the need of taking into account not only the seroconversion rate but also the development of T cell–mediated immunity in studies assessing the immunogenicity of SARS‐CoV‐2 vaccines in the SOT population 20 …”

Section: Discussionmentioning

confidence: 83%

T cell–mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19

Fernández‐Ruiz

Olea

Almendro-Vázquez

et al. 2021

American Journal of Transplantation

View full text Add to dashboard Cite

Whether immunosuppression impairs severe acute respiratory syndrome coronavirus 2‐specific T cell–mediated immunity (SARS‐CoV‐2‐CMI) after liver transplantation (LT) remains unknown. We included 31 LT recipients in whom SARS‐CoV‐2‐CMI was assessed by intracellular cytokine staining (ICS) and interferon (IFN)‐γ FluoroSpot assay after a median of 103 days from COVID‐19 diagnosis. Serum SARS‐CoV‐2 IgG antibodies were measured by ELISA. A control group of nontransplant immunocompetent patients were matched (1:1 ratio) by age and time from diagnosis. Post‐transplant SARS‐CoV‐2‐CMI was detected by ICS in 90.3% (28/31) of recipients, with higher proportions for IFN‐γ‐producing CD4+ than CD8+ responses (93.5% versus 83.9%). Positive spike‐specific and nucleoprotein‐specific responses were found by FluoroSpot in 86.7% (26/30) of recipients each, whereas membrane protein‐specific response was present in 83.3% (25/30). An inverse correlation was observed between the number of spike‐specific IFN‐γ‐producing SFUs and time from diagnosis (Spearman's rho: −0.418; p value = .024). Two recipients (6.5%) failed to mount either T cell–mediated or IgG responses. There were no significant differences between LT recipients and nontransplant patients in the magnitude of responses by FluoroSpot to any of the antigens. Most LT recipients mount detectable—but declining over time—SARS‐CoV‐2‐CMI after a median of 3 months from COVID‐19, with no meaningful differences with immunocompetent patients.

show abstract

Section: Discussionmentioning

confidence: 83%

T cell–mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19

Fernández‐Ruiz

Olea

Almendro-Vázquez

et al. 2021

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…3 We have also reported that robust T-cell responses can be observed as long as 6 months after infection with SARS-CoV-2 in a small cohort of patients with chronic myeloproliferative neoplasms including CML. 8 Furthermore, a number of additional studies have elegantly demonstrated the T-cell response to SARS-CoV-2 in the general population. [9][10][11][12][13] However, a recently submitted report describes a significantly reduced immune response in a heterogeneous group of patients with solid and haematological malignancies, 1 bringing concerns over the ability of clinically vulnerable patients with haematological malignancies to mount a protective response following a single dose of SARS-CoV-2 BNT162b2 vaccination.…”

Section: Discussionmentioning

confidence: 99%

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia

et al. 2021

Self Cite

View full text Add to dashboard Cite

Summary Patients receiving targeted cancer treatments such as tyrosine kinase inhibitors (TKIs) have been classified in the clinically extremely vulnerable group to develop severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), including patients with chronic myeloid leukaemia (CML) taking TKIs. In addition, concerns that immunocompromised individuals with solid and haematological malignancies may not mount an adequate immune response to a single dose of SARS‐CoV‐2 BNT162b2 (Pfizer‐BioNTech) vaccine have been raised. In the present study, we evaluated humoral and cellular immune responses after a first injection of BNT162b2 vaccine in 16 patients with CML. Seroconversion and cellular immune response before and after vaccination were assessed. By day 21 after vaccination, anti‐Spike immunoglobulin G was detected in 14/16 (87·5%) of the patients with CML and all developed a neutralising antibody response [serum dilution that inhibits 50% infection (ID 50 ) >50], including medium (ID 50 of 200–500) or high (ID 50 of 501–2000) neutralising antibodies titres in nine of the 16 (56·25%) patients. T‐cell response was seen in 14/15 (93·3%) evaluable patients, with polyfunctional responses seen in 12/15 (80%) patients (polyfunctional CD4 + response nine of 15, polyfunctional CD8 + T‐cell response nine of 15). These data demonstrate the immunogenicity of a single dose of SARS‐CoV‐2 BNT162b2 vaccine in most patients with CML, with both neutralising antibodies and polyfunctional T‐cell responses seen in contrast to patients with solid tumour or lymphoid haematological malignancies.

show abstract

“…The induction of virus-specific T-cell responses by BNT162b2 vaccination was assessed ex-vivo by flow cytometric enumeration of antigen-specific CD8+ and CD4+ T lymphocytes using an intracellular cytokine assay for IFNγ, TNFα and IL2, as described [ 11 ]. Briefly, cells were thawed, then rested for 18 h at 37 °C, 5% CO2.…”

Section: To the Editormentioning

confidence: 99%

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

et al. 2021

Self Cite

View full text Add to dashboard Cite

Evidence of robust memory T‐cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)

Cited by 13 publications

References 14 publications

T cell–mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19

T cell–mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

Contact Info

Product

Resources

About